TG THERAPEUTICS, INC. 8-K

What Happened

• On February 26, 2026, TG Therapeutics, Inc. announced results of operations for the three and twelve months ended December 31, 2025 via a press release.
• The company furnished that press release as Exhibit 99.1 to a Form 8-K (Item 2.02). The filing provides the condensed announcement of the company’s quarterly and full-year results.

Key Details

• Filing date: February 26, 2026 (Form 8-K).
• Periods covered: three months and twelve months ended December 31, 2025.
• Disclosure format: press release furnished as Exhibit 99.1 to the 8-K.

Why It Matters

• Quarterly and full-year results (earnings, revenue, operating results and cash position) are core inputs investors use to assess company performance and valuation; this 8-K signals that TG Therapeutics has publicly released that information.
• Retail investors should read the press release (Exhibit 99.1) and related SEC filings for the specific financial figures and any management commentary or guidance, since those details will drive near-term market reaction and inform investment decisions.